Clostridium Butyricum for stricturing Crohn's disease

This study looks at how bacteria in the gut may affect scar tissue (fibrosis) and the immune system in people with Crohn's disease. By comparing tissue samples from people with and without Crohn's, researchers hope to understand why some people develop narrowing or blockages, which could lead to better treatments.

This study tests a medicine called tirzepatide to see if it can help people with active Crohn’s disease who have not responded to multiple prior treatments. It focuses on how the drug might work beyond just reducing inflammation.

This trial tests a new approach that combines two procedures (stricturotomy and balloon dilation) against stricturotomy alone to treat short narrowed areas (strictures) caused by Crohn's disease. The goal is to see which method works better for keeping the bowel open longer.

This trial tests whether taking sodium butyrate (a short-chain fatty acid) and a specific probiotic yeast called Kluyveromyces marxianus can help keep ulcerative colitis in remission and prevent flare-ups. You'd need to be in remission (symptom-free with no active inflammation) when you start.

This trial tests a specific probiotic (a type of beneficial bacteria) to see if it can help people with mild to moderate ulcerative colitis by improving the balance of gut microbes. It may be an option if you have not used many advanced treatments before.

This trial tests whether butyrate can help children and teens with mild-to-moderate ulcerative colitis (a long-term bowel inflammation condition). You may be able to join if your symptoms fit the study level and you haven’t recently started other specific ulcerative colitis treatments right before the study begins.